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procedures (median age: 56.3 (22–82) years; median KPS: 80 (50–100)%. 
Histology revealed glioma WHO III° in 31.1% and WHO IV° in 68.9%. 
Lesions were localized in corpus callosum (50.0%), basal ganglia (18.9%), 
thalamus (9.0%), pineal region (2.5%), sella (0.8%), brainstem (18.9%). 
Median overall survival (mOS) was 6.3 months (95% CI, 3.6–9.0%), for 
WHO III°: 13.6 months (95% CI 5.6–21.6) and WHO IV°: 4.9 months (95 
% CI, 3.2–6.6). Patients were treated as follows: no specific tumor therapy 
(13.1%, 2 WHO III° and 15 WHO IV°; mOS 1.1 months) or various Tumor 
specific therapy regimens (WHO III° 34 (32.4%) patients mOS 15.5 month 
[95% CI 7.4–23.6]), (WHO IV° 65 (61.9%) patients mOS 10.6 months). In 
6 patients (5.7%) the type of adjuvant therapy is unknown. MGMT promo-
tor methylation status was available for 46 tumor treated patients (18 WHO 
III°, 28 WHO IV°). mOS of patients with WHO IV tumors was significantly 
worse than WHO III° (p<0.0001). Any tumor specific treatment improved 
survival significantly (p=0.005). Poor condition (KPS<70) and no tumor spe-
cific therapy were the significant factors for poor OS in multivariate analysis 
(adjusted HR 1.88 CI95% 1.03–3.92 p=0.04 and 11.09 CI95% 5.24–23.35 
p<0.0001 respectively).
CONCLUSION: Overall survival de novo HGG’s especially of WHO 
IV located in midline structures is poor. Specific tumor treatment improves 
survival significantly. Treatment decision should be based on the patient’s 
clinical status for the best quality of life.
P08.35 CLINICAL OUTCOMES FOR GLIOBLASTOMA PATIENTS 
WITH SOLITARY, MULTIFOCAL AND MULTICENTRIC DISEASE
T. Abdullah, R. N. Joseph, M. MacKinnon, A. Williamson, S. Nowicki, 
B. Clark, A. J. Chalmers, A. James
Beatson oncology centre, Glasgow, United Kingdom.
INTRODUCTION: Based on imaging features, glioblastoma (GBM) can 
be classified as solitary, multifocal or multicentric. The incidence of multifo-
cal/multicentric GBM has been reported to range from 0.5 to 35% and some 
studies have reported poorer survival in patients with multiple lesions. Two 
potential reasons have been proposed: (1) intrinsic differences in tumour 
biology; (2) failure to encompass the entire tumour within the radiotherapy 
planning tumour volume. To address this question we investigated clinical, 
imaging and genetic features in a cohort of GBM patients.
METHODS: Imaging, clinical, treatment, MGMT methylation and out-
come data were collected retrospectively from consecutive GBM patients 
treated in a single cancer centre between January 2011 and June 2012. 
Tumours were categorised as solitary, multifocal or multicentric by a con-
sultant neuroradiologist.
RESULTS: 122 patents with GBM were identified. Median age was 60 
and male:female ratio was 2.1:1. MGMT promoter status was unmethylated 
in 48% of tumours, methylated in 37% and unknown in 15%. Preoperative 
imaging modality was CT in 70% and MRI in 30% of patients. Overall, the 
proportion of patients with solitary, multifocal and multicentric tumours 
was 78%, 15.5% and 6.5 % respectively, but in patients undergoing MR 
imaging these proportions were 60%, 26.5% and 13.5%. Gross total resec-
tion was performed in 65% of solitary compared with 42% of multifocal 
and 25% of multicentric cases, and radical chemoradiation was delivered to 
50% of solitary, 58% of multifocal and 12% of multicentric cases. Over-
all, median survival was increased in solitary compared with multifocal/
multicentric patients (9.9 vs. 6.7 months, p = 0.046). In patients receiving 
radical chemoradiation, however, there was no difference in overall survival 
between solitary and multifocal/multicentric patients (18.5 vs. 16.8 months, 
p=0.57). MGMT promoter methylation was associated with increased sur-
vival in patients with solitary tumours (14.6 vs. 8.5 months, p= 0.014) but 
not multifocal/multicentric tumours (3.8 vs. 6.9 months, p= 0.3).
CONCLUSION: In this retrospective study the incidence of multifocal/
multicentric GBM was in line with previous studies. Pre-operative CT imag-
ing may underestimate the incidence of multifocal/multicentric disease. Our 
main finding was that multifocality or multicentricity did not affect survival 
in patients to whom radical chemo-radiotherapy could be delivered.
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1University of Sunderland, Sunderland, United Kingdom, 2University of 
Glasgow, Glasgow, United Kingdom, 3University of Oxford, Oxford, 
United Kingdom, 4CR-UK Beatson Institute, Glasgow, United Kingdom.
INTRODUCTION: The inevitability of tumour recurrence in glioblas-
toma (GBM) patients despite multi-modality treatment consisting of surgery, 
radiotherapy and chemotherapy, is reflected by a median survival of only 
14 months. Tumour recurrence is thought to be driven by a small popula-
tion of glioblastoma stem-like cells (GSCs) that are resistant to conventional 
therapies. DNA damage response (DDR) pathways have been shown to be 
up-regulated in GSCs and implicated in radioresistance and treatment fail-
ure. However the precise cause of enhanced DDR signalling in GSCs and the 
extent to which these signalling networks contribute to therapy resistance 
remains elusive. The objectives of this study were to investigate the underly-
ing cause of DDR upregulation and treatment resistance in GSCs with a 
view to identifying novel and promising therapeutic targets.
MATERIALS AND METHODS: A panel of primary patient derived 
GBM cell lines cultured under conditions to enrich for or deplete the tumour 
stem cell population (GSC vs bulk respectively) were utilised in order to 
investigate enhanced GSC DDR under basal conditions and in response to 
ionising radiation. Confirmatory studies were also performed in cells sorted 
for the putative GSC marker CD133. The effects of a panel of small molecule 
DDR inhibitor agents on cell survival in GSC and bulk cells were quantified.
RESULTS: GSCs exhibited higher levels of total and activated DDR 
targets ATR, CHK1, ATM and PARP1 under basal conditions and were 
radioresistant compared to paired bulk populations. This was not due to 
increased levels of reactive oxygen species (ROS). Instead, we show that RPA 
is significantly higher in replicating GSCs and confirm by DNA fibre assays 
that GSCs and CD133+ cells have increased numbers of stalled replication 
forks, fewer new origins and slower DNA replication compared to bulk or 
CD133- populations, demonstrating for the first time that replication stress 
(RS) is a hallmark of GSCs. We identify increased expression of long neural 
genes as a likely mechanism for RS and DNA double strand breaks (DSBs) 
in GSCs and show that their radioresistance is reversed by dual inhibition of 
key RS and DDR proteins ATR and PARP.
CONCLUSIONS: This study demonstrates the novel finding that replica-
tion stress is a hallmark of GSCs and resonates with recently published stud-
ies in neural progenitor cells showing that RS preferentially induces DNA 
DSB in long neural genes. Taken together, we implicate RS as a driver of 
enhanced DDR in GSCs and identify novel therapeutics with potential to 
improve clinical outcomes by overcoming the radioresistance of GBM.
P08.37 TUMOR ASSOCIATED M2 MACROPHAGE INFILTRATION 
IN GLIOBLASTOMA
T. Hori, T. Sasayama, K. Tanaka, H. Nagashima, J. Sakata, K. Mizukawa, 
M. Maeyama, E. Kohmura
Kobe University Graduate School of Medicine, Kobe, Japan.
INTRODUCTUION: Anti-inflammatory phenotype (M2) macrophage is 
known to secrete various cytokines and promote tumor-growth. However, 
the role of M2 macrophage in glioblastoma is not clear yet.
METHODS: We evaluated the specimens resected from thirty-three 
patients with glioblastoma, who underwent surgery at Kobe University Hos-
pital from November 2006 to December 2013. We investigated the infil-
tration of tumor-associated M2 macrophages by means of immunostaining 
for CD163, which is M2 cell marker. Also, we examined the association 
between infiltration levels of M2 macrophages and CSF cytokines (IL-6, 
IL-10, sIL-2R) by Spearman’s correlation coefficient by rank test. In addi-
tion, we examined the association between infiltration levels of M2 mac-
rophages and prognosis by Log-rank test.
RESULTS: The mean infiltration rate of CD163-positive M2 cells in 
all glioblastoma specimens was 23.9% (3.7~64.7%). CD163-positive M2 
macrophages tended to infiltrate in perivascular regions. Mean CSF con-
centration of IL-6, IL-10, IL-2R in all glioblastoma patients were 30.5 pg/
ml (0.8~292 pg/ml), <2 pg/ml (<2~5 pg/ml), and <50 pg/ml (<50~67 U/ml), 
respectively. The rate of CD163-positive M2 macrophage was significantly 
correlated with CSF IL-6 level (p<0.001). In relationship between CD163-
positive M2 cells and progression free survival (PFS), glioblastomas with 
higher levels of CD163-positive M2 cells had significant shorter PFS in com-
parison with those with lower levels of CD163-positive M2 cells (p=0.046). 
However, there is no relationship between levels of CD163-positive M2 cells 
and OS. On the other hand, the patients with higher levels of CSF IL-6 had 
significant shorter PFS (p=0158) and OS (p=0.0415) than that with lower 
levels of CSF IL-6.
CONCLUSIONS: We observed high infiltration of CD163-positive M2 
macrophages around the perivascular regions in glioblastoma. In addition, 
the infiltration levels of M2 macrophages correlated with IL-6 levels in CSF. 
The infiltration level of CD163-positive M2 macrophages may be associated 
with the prognosis of patients with glioblastomas.
P08.38 IRRADIATION OF SUBVENTRICULAR ZONE IN 
GLIOBLASTOMA: ITS IMPACT ON TUMOR PROGRESSION AND 
SURVIVAL
F. Sert, S. Hoca, S. Kamer, Y. Anacak
Ege University, Izmir, Turkey.
Irradiation of Subventricular Zone in Glioblastoma: Its Impact on Tumor 
Progression and Survival
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